Drug news
IB 1001 (Inspiration BioPharm) is filed at FDA for Haemophilia B
Inspiration Biopharmaceuticals has submitted a biologics license application (BLA) to the FDA for the approval of IB1001, an intravenous recombinant factor IX for the treatment and prevention of bleeding in Haemophilia B. The product has been filed at EMA by Ipsen and launches are expected in Europe in late 2012 or early 2013 and in the USA in early 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.